LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

bioMérieux and Hitachi Partnership to Focus on Microbiology and Molecular Diagnostics

By HospiMedica staff writers
Posted on 25 Mar 2008
bioMerieux (Marcy l'Etoile, France), an in-vitro diagnostics company, and Hitachi High-Technologies Corp.(Tokyo, Japan) have entered into a long-term strategic partnership. They plan to identify and develop new microbiology and molecular diagnostic systems.

New instruments developed under the partnership will be manufactured by Hitachi High-Technologies and distributed through bioMérieux's worldwide commercial network. bioMérieux is present in more than 150 countries through 38 subsidiaries and a large network of distributors. Teams from bioMérieux and Hitachi High-Technologies are working together toward development milestones on a new system.

"bioMérieux's vision, and a key objective of our 2012 strategy, is to bring full automation to microbiology laboratories around the world. This partnership enables bioMérieux to work with extremely talented engineers from Hitachi High-Technologies Corporation to better serve our customers,” said Stéphane Bancel, CEO of bioMérieux. "We will also introduce innovative systems to molecular diagnostics, leveraging bioMérieux's expertise in biology and Hitachi High-Technologies Corporation's remarkable engineering capabilities,” he added.


Related Links:
bioMerieux
Hitachi High-Technologies Corporation

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Automatic CLIA Analyzer
Shine i6000

Latest Industry News

New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
25 Mar 2008  |   Industry

Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada
25 Mar 2008  |   Industry

Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
25 Mar 2008  |   Industry